https://mindmedicinelaw.com/briefing/ketamine-s-antidepressant-brain-signal-implications-for-u-s-clinical-trials-and--20260921-43777The Psychedelic Journalen2026-09-21T15:06:01.813790+00:00Ketamine’s Antidepressant Brain Signal: Implications for U.S. Clinical Trials and Policyketamine, antidepressant biomarker, brain signal, clinical trials, precision psychiatry, FDA regulation, EEG, treatment-resistant depression, neurobiology, psychedelic researchhttps://mindmedicinelaw.com/briefing/non-hallucinogenic-psilocybin-trial-in-u-s-end-of-life-care-20260921-43776The Psychedelic Journalen2026-09-21T15:05:40.164631+00:00Non-Hallucinogenic Psilocybin Trial in U.S. End-of-Life Carepsilocybin, non-hallucinogenic dosing, end-of-life care, clinical trials, FDA, palliative care, psychedelic therapy, regulatory policy, neuroplasticity, psychoplastogenshttps://mindmedicinelaw.com/briefing/filament-s-pex010-psilocybin-heads-to-phase-3-in-u-s-palliative-care-20260921-43775The Psychedelic Journalen2026-09-21T15:05:18.351245+00:00Filament's PEX010 Psilocybin Heads to Phase 3 in U.S. Palliative Carepsilocybin, filament health, pex010, phase 3 trial, palliative care, psychological distress, fda approval, gmp manufacturing, psychedelic therapy, clinical researchhttps://mindmedicinelaw.com/briefing/fda-expands-cmc-pilot-program-implications-for-psychedelic-drug-sponsors-20260921-43692The Psychedelic Journalen2026-09-21T15:04:59.135765+00:00FDA Expands CMC Pilot Program: Implications for Psychedelic Drug Sponsorsfda cmc pilot, psychedelic drug development, investigational new drug, manufacturing quality, regulatory policy, federal register, clinical trials, expedited review, cbir cder, risk-based regulationhttps://mindmedicinelaw.com/briefing/dea-schedules-diphenidine-as-schedule-i-us-policy-and-research-impact-20260921-43690The Psychedelic Journalen2026-09-21T15:04:34.526456+00:00DEA Schedules Diphenidine as Schedule I: US Policy and Research Impactdea scheduling, diphenidine, schedule i substances, controlled substances act, research restrictions, dissociative drugs, 1971 convention, policy impact, us drug lawhttps://mindmedicinelaw.com/briefing/esketamine-dissociation-and-depression-clinical-implications-for-u-s-practice-20260920-43521The Psychedelic Journalen2026-09-20T15:04:21.122706+00:00Esketamine Dissociation and Depression: Clinical Implications for U.S. Practiceesketamine, dissociation, treatment-resistant depression, clinical trials, subjective effects, FDA, psychedelic therapy, risk-benefit assessment, precision psychiatryhttps://mindmedicinelaw.com/briefing/ayahuasca-in-preclinical-depression-models-new-evidence-from-brazil-20260919-43819The Psychedelic Journalen2026-09-21T22:05:32.394579+00:00Ayahuasca in Preclinical Depression Models: New Evidence from Brazilayahuasca, preclinical depression models, serotonergic psychedelics, animal research, bdnf, oxidative stress, translational research, psychedelic regulation, major depressive disorder, maternal deprivationhttps://mindmedicinelaw.com/briefing/first-iv-ketamine-case-for-trd-in-argentinian-public-hospital-20260919-43862The Psychedelic Journalen2026-09-21T22:05:18.993386+00:00First IV Ketamine Case for TRD in Argentinian Public Hospitalketamine, treatment-resistant depression, public hospital, argentina, psychedelic therapy, international adoption, clinical implementation, health policy, risk managementhttps://mindmedicinelaw.com/briefing/esketamine-for-perioperative-neuroprotection-clinical-evidence-and-future-direct-20260918-43864The Psychedelic Journalen2026-09-21T22:06:31.144219+00:00Esketamine for Perioperative Neuroprotection: Clinical Evidence and Future Directionsesketamine, perioperative neuroprotection, clinical trials, surgical outcomes, NMDA receptor antagonists, postoperative cognitive dysfunction, anesthesiology, neuroinflammation, public health, regulatory statushttps://mindmedicinelaw.com/briefing/human-myelin-mps-platform-implications-for-ms-and-psychedelic-cns-research-20260918-43875The Psychedelic Journalen2026-09-21T22:06:14.247003+00:00Human Myelin MPS Platform: Implications for MS and Psychedelic CNS Researchmyelin microphysiological system, multiple sclerosis, preclinical CNS models, personalized medicine, psychedelic research, neuroinflammation, demyelinating diseases, drug screening, translational neurosciencehttps://mindmedicinelaw.com/briefing/novel-nocebo-identification-protocol-in-n-of-1-psychedelic-trials-20260918-43856The Psychedelic Journalen2026-09-21T22:06:01.642521+00:00Novel Nocebo Identification Protocol in n-of-1 Psychedelic Trialsnocebo effects, psychedelic clinical trials, balanced placebo design, expectation effects, adverse event attribution, n-of-1 study, trial methodology, safety monitoring, open-blinded crossover, pharmacological effectshttps://mindmedicinelaw.com/briefing/fear-engrams-and-cognitive-dysfunction-new-mechanisms-in-mouse-models-20260918-43863The Psychedelic Journalen2026-09-21T22:05:47.980918+00:00Fear Engrams and Cognitive Dysfunction: New Mechanisms in Mouse Modelsfear engrams, dorsal dentate gyrus, cognitive dysfunction, affective dysfunction, mouse model, stress-related disorders, psychedelic research, neuromodulation, glutamatergic neurons, GABAergic neuronshttps://mindmedicinelaw.com/briefing/validated-short-form-peq-enhances-psychedelic-outcome-research-20260918-43821The Psychedelic Journalen2026-09-21T22:05:04.277778+00:00Validated Short-Form PEQ Enhances Psychedelic Outcome Researchpersisting effects questionnaire, peq-sf, psychedelic outcome measurement, clinical trial assessment, psychometric validation, participant burden, standardized research tools, positive and negative effects, public health data, neuroscience outcomeshttps://mindmedicinelaw.com/briefing/lsd-and-adaptive-stress-pathways-new-mechanistic-insights-from-mouse-prefrontal--20260918-43823The Psychedelic Journalen2026-09-21T22:04:51.493010+00:00LSD and Adaptive Stress Pathways: New Mechanistic Insights from Mouse Prefrontal Cortexlsd, psychedelics, hormesis, prefrontal cortex, adaptive stress, gene expression, neuroscience, clinical translation, risk assessment, psychiatric researchhttps://mindmedicinelaw.com/briefing/pharmaceutical-management-of-suds-hallucinogens-in-clinical-context-20260917-43840The Psychedelic Journalen2026-09-21T22:06:57.639733+00:00Pharmaceutical Management of SUDs: Hallucinogens in Clinical Contextsubstance use disorder, hallucinogens, psychedelic-assisted therapy, opioid use disorder, pharmaceutical management, clinical trials, precision dosing, biomarkers, harm reduction, translational researchhttps://mindmedicinelaw.com/briefing/ecstatic-phenomena-in-epilepsy-surgery-neural-localization-insights-20260917-43829The Psychedelic Journalen2026-09-21T22:06:46.299658+00:00Ecstatic Phenomena in Epilepsy Surgery: Neural Localization Insightsecstatic seizures, epilepsy surgery, insular cortex, temporal lobe, altered states of consciousness, psychedelic neuroscience, systematic review, neural correlates, clinical research, translational sciencehttps://mindmedicinelaw.com/briefing/patient-expectations-shape-ketamine-outcomes-in-depression-care-20260916-43448The Psychedelic Journalen2026-09-20T15:04:32.166330+00:00Patient Expectations Shape Ketamine Outcomes in Depression Careketamine, treatment-resistant depression, patient expectations, psychedelic therapy, qualitative research, clinical trial design, subjective experience, psychological context, mental health policy